James E. Audia - Concepedia

Author

James E. Audia

Also Known As

Audia, J.E., J E Audia, J. Audia, J. E. AUDIA, J. E. Audia, J.E. Audia, JE Audia, James Audia, James E Audia, James E. Audia

129

Publications

7.5K

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Constellation Pharmaceuticals (United States)WuXi AppTec (China)

About

James E. Audia is an author at Eli Lilly (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	27	40	4.5K
2	Natural Sciences	19	21	1.5K
3	Biochemistry	19	24	2.2K
4	Engineering	6	6	199
5	Social Sciences	5	5	1.9K

James E. Audia

Publications

6.3K

Citations

H-Index

Page 1

	Year	Citations
Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain Harry F. Dovey, Varghese John, J. P. Anderson, Journal of Neurochemistry Protein SecretionNeurochemical BiomarkersAmyloid Precursor ProteinSocial SciencesAlzheimer's Disease	2001	877
The promise and peril of chemical probes C.H. Arrowsmith, James E. Audia, Christopher P. Austin, Nature Chemical Biology	2015	836
In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-beta metabolism and half-life. John R. Cirrito, Patrick C. May, Mark Odell, PubMed Vivo AssessmentSocial SciencesAlzheimer's DiseaseBrain Interstitial FluidIsf Abeta Half-life	2003	426
<i>In Vivo</i>Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life John R. Cirrito, Patrick C. May, Mark Odell, Journal of Neuroscience Amyloid-β MetabolismIsf Aβ Half-lifeSocial SciencesNeuroinflammationAlzheimer's Disease	2003	406
Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor Patrick C. May, Robert A. Dean, Stephen L. Lowe, Journal of Neuroscience Robust Central ReductionAmyloid-β PeptideNeurochemical BiomarkersPeptide ScienceAmyloid Precursor Protein	2011	365
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials Brian K. Albrecht, Victor Gehling, Michael C. Hewitt, Journal of Medicinal Chemistry ImmunologyPharmacotherapyTumor BiologyMyeloid NeoplasiaHematological Malignancy	2016	214
Identification of (<i>R</i>)-<i>N</i>-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1<i>H</i>-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas Rishi G. Vaswani, Victor Gehling, Les A. Dakin, Journal of Medicinal Chemistry	2016	214
The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans Patrick C. May, Brian A. Willis, Stephen L. Lowe, Journal of Neuroscience Amyloid βNeurodegenerative DiseasesAmyloid LoweringAlzheimer's DiseaseKey Protease	2015	195
5-HT1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs Kirk W. Johnson, John M. Schaus, Margaret M. Durkin, Neuroreport NeurotransmitterImmunologySocial SciencesNeuroinflammationInflammation	1997	158
Identification of EZH2 and EZH1 Small Molecule Inhibitors with Selective Impact on Diffuse Large B Cell Lymphoma Cell Growth Shivani Garapaty-Rao, Christopher G. Nasveschuk, Alexandre Gagnon, Chemistry & Biology Hematological MalignancyTumor BiologyLymphoid NeoplasiaMedicineSmall Molecules	2013	154

Page 1